Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 16, 2018. The report details the vesting of conditional share awards granted in 2015 under the GlaxoSmithKline Performance Share Plan (PSP) to Persons Discharging Managerial Responsibilities (PDMRs). The performance period for these awards spanned from January 1, 2015, to December 31, 2017.
Key Financial Metrics and Performance Outcomes
The filing does not report consolidated revenue, profit, cash flow, or debt metrics for the company. Instead, it discloses specific performance metrics used to determine executive compensation vesting for the 2015 awards:
- Adjusted Free Cash Flow: Achieved £12.47 billion against a threshold of £11.48 billion (63% of maximum vesting).
- Total Shareholder Return (TSR): Ranked 5th against a comparator group of 10 global pharmaceutical companies (44% of maximum vesting).
- R&D New Products: Achieved sales of £11.266 billion against a maximum vesting threshold of £7.912 billion (100% of maximum vesting).
Share Prices at Vesting (February 15, 2018):
- Ordinary Share: £13.004
- American Depositary Share (ADS): $37.31
Material Changes and Vesting Results
The filing reports the outcome of the three-year performance period. The total vesting level for the 2015 awards was 69%, with 31% of the awards lapsing. The vesting was calculated based on the weighted average of the three performance measures listed above. Specific vesting volumes for individual PDMRs are detailed in the transaction notifications, with shares vesting at a price of £0.00 or $0.00 as they were granted awards.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, management commentary on future strategy, or discussion of risks and contingencies. It is strictly a notification of equity transactions. One unusual item noted is that the shares vested for the Chief Financial Officer (Mr. S. Dingemans) are subject to a two-year holding period ending in 2020. Additionally, awards for Mr. B. McNamara were made to compensate for the value of awards forfeited upon the completion of the Joint Venture with Novartis.
Investor Verification Checklist
- Verify the specific vesting percentages (69% total) against the disclosed performance thresholds for Free Cash Flow, TSR, and R&D sales.
- Confirm the total number of shares vested for each named PDMR to assess executive compensation alignment.
- Note the holding period restriction on the CFO's vested shares until 2020.
- Review the Novartis Joint Venture context regarding the specific ADS awards granted to Mr. McNamara.